Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Paul Nghiem, Shailender Bhatia, Evan J Lipson, William H Sharfman, Ragini R Kudchadkar, Andrew S Brohl, Philip A Friedlander, Adil Daud, Harriet M Kluger, Sunil A Reddy, Brian C Boulmay, Adam Riker, Melissa A Burgess, Brent A Hanks, Thomas Olencki, Kari Kendra, Candice Church, Tomoko Akaike, Nirasha Ramchurren, Michi M Shinohara, Bob Salim, Janis M Taube, Erin Jensen, Mizuho Kalabis, Steven P Fling, Blanca Homet Moreno, Elad Sharon, Martin A Cheever, Suzanne L Topalian
Journal for ImmunoTherapy of Cancer Apr 2021, 9 (4) e002478; DOI: 10.1136/jitc-2021-002478